Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal murine CD4<sup>+</sup> T cell priming by mRNA-lipid nanoparticle vaccines requires endogenous antigen processing.

Nature communications·2026
Same author

ULTRA-Metrics: Delphi-Derived Framework for Assessing Ultrasound Competency.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2025
Same author

Aiding Chronic Obstructive Pulmonary Disease and Congestive Heart Failure Ultrasound-Guided Management Through Enhanced Point-of-Care Ultrasound (ACCUMEN-POCUS): Protocol for a Randomized Controlled Trial.

JMIR research protocols·2025
Same author

Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications.

Nature nanotechnology·2025
Same author

From the periphery to inclusion within the health system: promoting community health worker empowerment as a way forward.

BMC primary care·2024
Same author

Evaluating the new family medicine internship programmes in the Western Cape, South Africa.

South African family practice : official journal of the South African Academy of Family Practice/Primary Care·2024
Same journal

Design Principles for Fluid Molecular Ferroelectrics.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

Generating Unconventional Spin-Orbit Torques With Patterned Phase Gradients in Tungsten Thin Films.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

An In Situ H<sub>2</sub>S-Activated Plasmonic Nanozyme for Near-Infrared II Photo-Thermoelectric Catalytic Therapy.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

A Recyclable and Sustainable Hydroxypropyl Methylcellulose Electrolyte for Electrochromic Devices.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

Perovskite Heterostructures for Optoelectronic Applications.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

Light-Written Nonvolatile Polarization via Defect-Engineered Charge Trapping.

Advanced materials (Deerfield Beach, Fla.)·2026
See all related articles

Related Experiment Video

Updated: Aug 5, 2025

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.4K

Optimizing Lipid Nanoparticles for Delivery in Primates.

Kieu Lam1, Petra Schreiner1, Ada Leung1

  • 1Genevant Sciences Corporation, Vancouver, BC, V5T 4T5, Canada.

Advanced Materials (Deerfield Beach, Fla.)
|March 27, 2023
PubMed
Summary
This summary is machine-generated.

Optimizing lipid nanoparticle (LNP) formulations for non-human primates (NHPs) significantly enhances messenger RNA (mRNA) delivery. Adjusting particle size and surface chemistry boosts potency eight-fold, crucial for preclinical drug development.

Keywords:
PEG shieldinglipid nanoparticlesnanotechnologynucleic acidparticle sizepotency translationtherapeutics

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.6K
Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins
11:30

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

24.0K

Related Experiment Videos

Last Updated: Aug 5, 2025

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

23.4K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.6K
Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins
11:30

Preparation and Characterization of Nanoliposomes for the Entrapment of Bioactive Hydrophilic Globular Proteins

Published on: August 31, 2019

24.0K

Area of Science:

  • Biotechnology
  • Drug Delivery
  • Nanomedicine

Background:

  • Lipid nanoparticles (LNPs) are proven carriers for RNA therapeutics and vaccines.
  • Non-human primates (NHPs) are key models for predicting human response to therapeutics.
  • Translating LNP potency from rodents to NHPs for intravenous delivery remains a challenge in preclinical development.

Purpose of the Study:

  • To investigate how LNP parameters optimized in rodents affect potency in NHPs.
  • To identify key LNP characteristics that influence delivery efficiency across species.
  • To optimize LNP formulations for enhanced messenger RNA (mRNA) delivery in NHPs.

Main Methods:

  • Systematic investigation of LNP particle size and surface chemistry (PEGylation).
  • Comparative potency assessment of LNP formulations in rodent and NHP models.
  • Evaluation of protein expression following intravenous administration of mRNA-LNPs in NHPs.

Main Results:

  • Optimal LNP particle size for NHPs (50-60 nm) differs from that in rodents (70-80 nm).
  • NHPs require approximately double the amount of poly(ethylene glycol) (PEG)-conjugated lipid for maximal potency compared to rodents.
  • Optimized LNPs achieved an eight-fold increase in protein expression in NHPs with good tolerability upon repeated administration.

Conclusions:

  • LNP formulation parameters require species-specific optimization for effective preclinical translation.
  • Adjustments in particle size and PEGylation significantly enhance mRNA-LNP potency in NHPs.
  • Optimized LNP formulations pave the way for improved clinical development of RNA-based therapeutics.